Bristol Myers Squibb posted a solid quarter and a clear growth story: Q4 revenue topped estimates, the Growth Portfolio now makes up half the business, and analysts put a $70.12 price target on the stock — about 16.5% above the current level. Investors are watching an active pipeline with several pivotal readouts slated for late 2026 that could reshape the company’s trajectory. That upside sits alongside real risks from legacy-product erosion and a hefty $49 billion debt load.
Q4 2025 revenue came in at $12.5 billion, narrowly beating expectations, and the Growth Portfolio reached $7.39 billion, up 16% year-over-year. High-growth assets drove the quarter: Breyanzi grew 49%, Camzyos 59%, and Opdualag 38%. Those gains helped offset declines in some older products and supported a more constructive market reaction to the results.
The stock trades around $60.17 as of writing, and the 24/7 Wall St. model shows a $70.12 price target — implying roughly 16.51% upside — with a BUY rating and a 90% confidence level. That mix of valuation upside and model conviction makes the shares interesting to investors looking for exposure to biotech transition. The market is treating BMY as a name in shift from legacy cash flow to a growth-driven lineup.
The pipeline is the headline risk-reward story. Iberdomide carries an FDA priority review with a decision expected in August 2026, and pivotal Milvexian data in stroke prevention is on the calendar. Other programs include pivotal IPF readouts for admilparant and advancing work in Alzheimer’s Disease Psychosis for cobenfy. A favorable sequence of readouts could materially change the company’s revenue mix and investor sentiment.
Management is bullish and clear about the path forward, and CEO Christopher Boerner stated: “2026 is data-rich, and we are advancing a truly differentiated pipeline with multiple pivotal readouts expected in the back half of the year. Our core business is strong and growing, and we have the potential to achieve industry-leading, sustainable growth into the 2030s and beyond.” That exact message frames the company’s cadence for the next 12 to 18 months.
That optimism comes with concrete headwinds. Legacy products showed steep declines in Q4 2025: Revlimid fell 55%, Sprycel dropped 60%, and Abraxane slid 52%, and U.S. generic pomalidomide entry was expected in Q1 2026. The company’s 2026 revenue guidance of $46 billion to $47.5 billion implies a year-over-year decline from 2025’s $48.194 billion, highlighting the transition’s near-term drag. The debt burden — roughly $49 billion, largely from the Celgene acquisition — remains a focal point for credit-sensitive investors.
There were accounting items that influenced the headline EPS in Q4. Reported EPS missed the headline estimate, with $1.26 reported versus a $1.63 estimate, driven by a $1.39 billion Acquired IPRD charge tied to an acquisition that depressed EPS by roughly $0.60 per share. On an adjusted basis, full-year 2025 non-GAAP EPS came in at $6.15, slightly above the $6.11 estimate, and the market responded positively with a modest post-earnings pop.
The bull case leans on gross-profit expansion and operational improvements. Bulls point out gross profit grew nearly 25% in 2025 despite flat revenue, and a productivity program is targeting $3.5 billion in savings by 2027. Eliquis, the company’s biggest drug, is guiding for 10%–15% worldwide revenue growth in 2026, which would provide a stable cash base while newer assets scale.
Valuation is part of the appeal for those taking the bullish view: shares trade at roughly 9 times forward earnings, the company pays a $2.52 annual dividend and has raised that payout for 17 consecutive years. Model scenarios show a bull path toward higher targets and a bear case that would leave the price roughly flat near current levels, so outcomes hinge heavily on clinical success and execution. Investors should weigh dividend reliability and valuation against binary clinical catalysts.
| Metric | Value |
|---|---|
| Current Price | $60.17 |
| Price Target | $70.12 |
| Upside/Downside | +16.51% |
| Model Rating | BUY |
| Confidence Level | 90% |
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $70.12 |
| 2027 | $76.00 |
| 2028 | $83.00 |
| 2029 | $91.00 |
| 2030 | $100.88 |
Key catalysts to monitor are the Iberdomide FDA decision and Milvexian stroke-prevention readouts in the back half of 2026, which could meaningfully alter the trajectory. Equally important are execution on cost savings, stabilization of legacy revenue declines, and any shifts in drug-pricing policy that could affect margins. For active investors, the story is a mix of near-term transition noise and potentially game-changing clinical milestones.
